Randomized, double-blinded trial of low-dose dexamethasone: II. Functional residual capacity and pulmonary outcome in very low birth weight infants at risk for bronchopulmonary dysplasia

Pediatric Pulmonology

Volumn 38, Issue 1, 2004, Pages 55-63

  McEvoy, Cindy ^a,c   Bowling, Susan ^a   Williamson, Kathleen ^a   McGaw, Pam ^a   Durand, Manuel ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Chronic lung disease; Functional residual capacity; Low dose dexamethasone; Lung volume; Preterm infants

Indexed keywords

DEXAMETHASONE;

ARTICLE; CHILD DEVELOPMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ENDOTRACHEAL INTUBATION; FOLLOW UP; FUNCTIONAL RESIDUAL CAPACITY; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LEUKOMALACIA; LOW DRUG DOSE; LUNG COMPLIANCE; LUNG DYSPLASIA; LUNG FUNCTION; LUNG VOLUME; NECROTIZING ENTEROCOLITIS; NERVE CELL DIFFERENTIATION; NEWBORN; NITROGEN WASHOUT; OXYGEN TENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; VERY LOW BIRTH WEIGHT;

ANALYSIS OF VARIANCE; BRONCHOPULMONARY DYSPLASIA; CHI-SQUARE DISTRIBUTION; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FUNCTIONAL RESIDUAL CAPACITY; HUMANS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS, NEONATAL; LUNG COMPLIANCE; MALE; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 3042544531     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.20037     Document Type: Article

References (40)

1. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants (Cochrane review). In: The Cochrane library, issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.
2. Bhuta T, Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch Dis Child Fetal Neonatal Ed 1998;79:26-33.
3. Durand M, Sardesai S, McEvoy C. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. Pediatrics 1995;95:584-590.
4. Brozanski BS, Jones JG, Gilmour CH, Balsan MJ, Vazquez RL, Israel BA, et al. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. J Pediatr 1995;126:769-776.
5. Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics 2001;108:741-748.
6. Sanders RJ, Cox C, Phelps DL, Sinkin RA. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatr Res 1994;36:122-128.
7. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989;320:1505-1510.
8. McEvoy C, Bowling S, Williamson K, Stewart M, Durand M. Functional residual capacity and passive compliance measurements after antenatal steroid therapy in preterm infants. Pediatr Pulmonol 2001;31:425-430.
9. McEvoy C, Bowling S, Williamson K, Collins J, Tolaymat L, Maher J. Timing of antenatal corticosteroids and neonatal pulmonary mechanics. Am J Obstet Gynecol 2000;183:895-899.
10. Cotton RB, Olsson T, Law AB, Parker RA, Lindstrom DP, Silberberg AR, et al. The physiologic effects of surfactant treatment on gas exchange in newborn premature infants with hyaline membrane disease. Pediatr Res 1993;34:495-501.
11. Jobe A. The new BPD: an arrest of lung development. Pediatr Res 1999;46:641-643.
12. Jobe AH, Ikegami M. Lung development and function in preterm infants in the surfactant treatment era. Annu Rev Physiol 2000;62:825-846.
13. Durand M, Mendoza ME, Tantivit P, Kugelman A, McEvoy C. A randomized trial of moderately early low dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation, and ventilation. Pediatrics 2002;109: 262-268.
14. Gerhardt T, Hehre D, Bancalari E, Watson H. A simple method for measuring functional residual capacity by N2 washout in small animals and newborn infants. Pediatr Res 1985;19:1165-1169.
15. Yuksel B, Greenough A, Chan V, Russell RR. Comparison of helium dilution and nitrogen washout measurements of functional residual capacity in premature infants. Pediatr Pulmonol 1993; 16:197-200.
16. McEvoy C, Bowling S, Williamson K, Lozano D, Tolaymat L, Izquierdo L, et al. The effect of a single remote course versus weekly courses of antenatal corticosteroids on functional residual capacity in preterm infants: a randomized trial. Pediatrics 2002; 110:280-284.
17. LeSouef PN, England SJ, Bryan AC. Passive respiratory mechanics in newborns and children. Am Rev Respir Dis 1984; 129:552-556.
18. Kelly E, Bryan H, Possmayer F, Frndova H, Bryan C. Compliance of the respiratory system in newborn infants pre- and post-surfactant replacement therapy. Pediatr Pulmonol 1993;15:225-230.
19. American Thoracic Society/European Respiratory Society. Respiratory mechanics in infants: physiologic evaluation in health and disease. Am Rev Respir Dis 1993;147:474-496.
20. McEvoy C, Mendoza ME, Bowling S, Hewlett V, Sardesai S, Durand M. Prone positioning decreases episodes of hypoxemia in extremely low birth weight infants (1000 grams or less) with chronic lung disease. J Pediatr 1997;130:305-309.
21. Durand M, McEvoy C, MacDonald K. Spontaneous desaturations in intubated very low birth weight infants with acute and chronic lung disease. Pediatr Pulmonol 1992;13:136-142.
22. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001;344: 1966-1972.
23. Kavvadia V, Greenough A, Dimitriou G, Itakura Y. Lung volume measurements in infants with and without chronic lung disease. Eur J Pediatr 1998;157:336-339.
24. Shao H, Sandberg K, Hjalmarson O. Impaired gas mixing and low lung volume in preterm infants with mild chronic lung disease. Pediatr Res 1998;43:536-541.
25. Kugelman A, Durand M, Garg M. Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia. Pediatrics 1997;99:71-75.
26. McCann EM, Goldman SL, Brady JP. Pulmonary function in the sick newborn infant. Pediatr Res 1987;21:313-324.
27. Bancalari E, Sosenko I. Pathogenesis and prevention of neonatal chronic lung disease: recent developments. Pediatr Pulmonol 1990;8:109-116.
28. Groneck P, Reuss D, Gotze-Speer B, Speer CP. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. J Pediatr 1993;122:938-944.
29. Watts CL, Bruce MC. Effect of dexamethasone therapy on fibronectin and albumin levels in lung secretions of infants with bronchopulmonary dysplasia. J Pediatr 1992;121:597-607.
30. Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 1995; 173:254-262.
31. Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. Pediatrics 2002; 109. Available at: http://www. pediatrics.org/cgi/content/full/109/6/e85.
32. Stark AR, Carlo WA, Tyson JE, Papile L-A, Wright LL, Shankaran S, et al. Adverse effects of early dexamethasone treatment in extremely low birth weight infants. N Engl J Med 2001;344:95-101.
33. O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999;104:15-21.
34. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998; 101. Available at: http://www.pediatrics.org/cgi/content/full/101/5/e7.
35. Yeh TF, Lin YJ, Huang CC, Lin HC, Hsieh WS, Tsai CH. School-age outcome in children with early postnatal dexamethasone therapy for prevention of CLD of prematurity. Pediatr Res 2003;53:438.
36. Banks BA. Postnatal dexamethasone for bronchopulmonary dysplasia: a systematic review and meta-analysis of 20 years of clinical trials. Neoreviews 2002;3. Available at: http://neoreviews.aappublications.org/cgi/content/full/3/ 2/e24.
37. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998;19:269-301.
38. Metzger DL, Wright NM, Veldhuis JD, Rogol AD, Kerrigan JR. Characterization of pulsatile secretion and clearance of plasma cortisol in premature and term neonates using deconvolution analysis. J Clin Endocrinol Metab 1993;77:458-463.
39. Munck A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 1984;5:25-44.
40. American Academy of Pediatrics, Committee on Fetus and Newborn and Canadian Pediatric Society, Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109:330-338.